Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Filings indexed 1,392 across all filing types
Latest filing 2018-03-07 Director's Dealing
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2018-03-07 English
PRIMARY DOCUMENT
Director's Dealing
2018-03-07 English
PRIMARY DOCUMENT
Director's Dealing
2018-03-07 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events or material definitive agreements by a company. The text describes Ligand Pharmaceuticals entering into a License Agreement with Roivant Sciences, detailing the terms of the agreement, milestone payments, royalties, and other contractual provisions. It also includes forward-looking statements and financial guidance updates related to this transaction. There are no comprehensive financial statements or detailed quarterly/yearly financial data presented, so it is not an Annual Report (10-K) or Interim Report (IR). The document is not a transcript, proxy, or governance report. It is a regulatory announcement of a material contract and related financial guidance, typical of an 8-K filing. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings like 8-Ks that do not fit other categories.
2018-03-06 English
10-K
Annual Report FY 2017
2018-03-01 English
PRIMARY DOCUMENT
Director's Dealing
2018-02-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.